Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 24 04:00PM ET
0.9300
Dollar change
-0.0200
Percentage change
-2.11
%
Index- P/E- EPS (ttm)-1.89 Insider Own37.11% Shs Outstand21.41M Perf Week-2.13%
Market Cap19.91M Forward P/E- EPS next Y-0.94 Insider Trans0.00% Shs Float13.47M Perf Month-81.25%
Income-40.16M PEG- EPS next Q-0.23 Inst Own40.76% Short Float5.94% Perf Quarter-18.42%
Sales0.00M P/S- EPS this Y45.77% Inst Trans-1.96% Short Ratio0.70 Perf Half Y-4.62%
Book/sh0.52 P/B1.77 EPS next Y8.29% ROA-103.63% Short Interest0.80M Perf Year-15.45%
Cash/sh0.60 P/C1.55 EPS next 5Y- ROE-136.38% 52W Range0.61 - 9.37 Perf YTD-21.19%
Dividend Est.- P/FCF- EPS past 5Y-193.22% ROI-319.67% 52W High-90.08% Beta1.14
Dividend TTM- Quick Ratio2.63 Sales past 5Y0.00% Gross Margin- 52W Low52.46% ATR (14)0.60
Dividend Ex-Date- Current Ratio2.63 EPS Y/Y TTM39.30% Oper. Margin0.00% RSI (14)31.41 Volatility10.58% 18.13%
Employees42 Debt/Eq0.22 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price9.00
Option/ShortNo / Yes LT Debt/Eq0.12 EPS Q/Q64.18% Payout- Rel Volume0.40 Prev Close0.95
Sales Surprise- EPS Surprise37.28% Sales Q/Q- EarningsMar 29 BMO Avg Volume1.14M Price0.93
SMA20-69.84% SMA50-77.08% SMA200-46.37% Trades Volume457,554 Change-2.11%
Date Action Analyst Rating Change Price Target Change
Jan-14-22Initiated H.C. Wainwright Buy $25
Dec-23-21Initiated Cantor Fitzgerald Overweight $25
Nov-01-21Initiated SVB Leerink Outperform $24
Sep-13-21Initiated Laidlaw Buy $30
Aug-25-21Initiated B. Riley Securities Buy $26
Apr-09-24 01:34PM
12:29PM
08:40AM
Apr-08-24 04:30PM
Apr-02-24 07:53AM
08:00AM Loading…
Apr-01-24 08:00AM
Mar-29-24 04:51PM
03:20PM
Mar-14-24 09:38AM
Mar-05-24 04:31PM
Jan-07-24 03:00PM
Dec-10-23 12:00PM
Nov-14-23 07:00AM
Nov-02-23 09:10AM
Oct-13-23 09:12AM
09:30AM Loading…
Oct-06-23 09:30AM
Sep-19-23 07:00AM
Sep-14-23 07:00AM
Aug-22-23 07:30AM
Aug-07-23 09:25AM
May-11-23 04:05PM
Apr-19-23 09:05AM
Apr-17-23 01:35PM
08:00AM
Mar-28-23 04:05PM
Mar-14-23 04:35PM
Feb-06-23 08:00AM
Dec-13-22 09:29AM
Dec-12-22 04:05PM
Dec-11-22 10:05AM
04:05PM Loading…
Nov-10-22 04:05PM
Nov-03-22 09:05AM
Aug-11-22 04:05PM
09:43AM
Jul-01-22 06:03AM
Jun-10-22 08:00AM
Jun-07-22 02:11PM
08:25AM
Jun-06-22 04:05PM
06:24AM
May-12-22 04:05PM
Apr-08-22 01:05PM
Mar-29-22 08:00AM
Mar-08-22 04:35PM
Feb-09-22 08:00AM
Feb-03-22 08:30AM
Jan-30-22 06:32PM
Dec-28-21 09:35AM
Dec-17-21 08:00AM
Dec-11-21 03:30PM
Dec-07-21 08:00AM
Dec-06-21 08:00AM
Nov-12-21 08:00AM
Nov-04-21 09:01AM
Sep-16-21 07:30AM
Sep-07-21 08:00AM
Aug-12-21 04:05PM
Jul-30-21 09:55AM
Jul-01-21 02:42AM
Jun-28-21 08:00AM
Jun-04-21 12:40PM
08:00AM
Jun-03-21 04:05PM
May-26-21 08:00AM
May-17-21 08:00AM
May-06-21 08:00AM
Apr-20-21 08:00AM
Apr-10-21 08:31AM
Apr-07-21 08:00AM
Apr-05-21 08:00AM
Apr-01-21 08:00AM
Mar-30-21 09:24AM
Mar-23-21 08:00AM
Mar-10-21 04:32PM
Mar-02-21 08:00AM
Feb-24-21 08:00AM
Feb-17-21 08:00AM
Jan-07-21 04:01PM
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. It focuses on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The firm pipeline is derived from a license agreement with Bayer and includes: a clinical-stage and follow-on small molecule drug program and preclinical stage bioconjugation/next-generation antibody-drug conjugate platform. The company was founded by Ahmed M. Hamdy, Raquel E. Izumi, Tom C. Thomas, Soo In Hwang and John C. Byrd on December 19, 2018 and is headquartered in Palo Alto, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Seelenberger Alexander A.See RemarksAug 11 '23Buy0.9510,5009,96830,280Aug 14 04:09 PM
Hamdy Ahmed MDSee RemarksAug 10 '23Buy0.965,4005,16796,060Aug 10 06:28 PM
THOMAS TOM CSee RemarksAug 10 '23Buy0.955,0004,750219,935Aug 10 06:28 PM
Izumi Raquel E.See RemarksAug 10 '23Buy0.933,4403,19985,214Aug 10 06:27 PM
Hamdy Ahmed MDSee RemarksAug 09 '23Buy0.9516,90015,99490,660Aug 10 06:28 PM
Izumi Raquel E.See RemarksAug 09 '23Buy0.9013,03611,73581,774Aug 10 06:27 PM